NCT02465528 - Ceritinib Rare Indications Study in ALK+ Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 6, 2016

Primary Completion Date

August 20, 2018

Study Completion Date

August 20, 2018

Conditions

Tumors With Aberrations in ALKAnaplastic Large Cell LymphomaInflammatory Myofibroblastic TumorGlioblastoma

Interventions

DRUG

Ceritinib (LDK378)

Ceritinib was to be administered orally once daily at a dose of 750 mg (5 capsules of 150 mg) on a continuous dosing schedule. A complete treatment cycle was defined as 28 days of once daily continuous treatment with ceritinib.

Trial Locations (14)

10330

Novartis Investigative Site, Bangkok

10700

Novartis Investigative Site, Bangkok

20133

Novartis Investigative Site, Milan

28034

Novartis Investigative Site, Madrid

28040

Novartis Investigative Site, Madrid

44805

Novartis Investigative Site, Saint-Herblain Cédex

69373

Novartis Investigative Site, Lyon

6423906

Novartis Investigative Site, Tel Aviv

656 53

Novartis Investigative Site, Brno

DK-2100

Novartis Investigative Site, Copenhagen

F 67085

Novartis Investigative Site, Strasbourg

03080

Novartis Investigative Site, Seoul

03722

Novartis Investigative Site, Seoul

06351

Novartis Investigative Site, Seoul